WO2008155537A2 - Dispensing apparatus - Google Patents
Dispensing apparatus Download PDFInfo
- Publication number
- WO2008155537A2 WO2008155537A2 PCT/GB2008/002071 GB2008002071W WO2008155537A2 WO 2008155537 A2 WO2008155537 A2 WO 2008155537A2 GB 2008002071 W GB2008002071 W GB 2008002071W WO 2008155537 A2 WO2008155537 A2 WO 2008155537A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- inhalation apparatus
- dispensing container
- housing
- section
- cross sectional
- Prior art date
Links
- 238000007493 shaping process Methods 0.000 claims description 17
- 238000003780 insertion Methods 0.000 claims description 4
- 230000037431 insertion Effects 0.000 claims description 4
- 239000000853 adhesive Substances 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- 239000000126 substance Substances 0.000 abstract description 2
- -1 for example Chemical class 0.000 description 7
- 229940126601 medicinal product Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 2
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 2
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 2
- 150000001241 acetals Chemical class 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 229940092705 beclomethasone Drugs 0.000 description 2
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 2
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- 229960000676 flunisolide Drugs 0.000 description 2
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000007373 indentation Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 2
- 229960002052 salbutamol Drugs 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229960000195 terbutaline Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- NDAUXUAQIAJITI-LBPRGKRZSA-N (R)-salbutamol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 description 1
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- RPHLQSHHTJORHI-UHFFFAOYSA-N Adrenochrome Chemical compound O=C1C(=O)C=C2N(C)CC(O)C2=C1 RPHLQSHHTJORHI-UHFFFAOYSA-N 0.000 description 1
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102400000739 Corticotropin Human genes 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- AKNNEGZIBPJZJG-UHFFFAOYSA-N alpha-noscapine Natural products CN1CCC2=CC=3OCOC=3C(OC)=C2C1C1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-UHFFFAOYSA-N 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 229950000210 beclometasone dipropionate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- NTXGQCSETZTARF-UHFFFAOYSA-N buta-1,3-diene;prop-2-enenitrile Chemical compound C=CC=C.C=CC#N NTXGQCSETZTARF-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 229950005627 embonate Drugs 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 229960004943 ergotamine Drugs 0.000 description 1
- OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 1
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229950000206 estolate Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 229960000289 fluticasone propionate Drugs 0.000 description 1
- 229960002848 formoterol Drugs 0.000 description 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960001067 hydrocortisone acetate Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
- 229960001410 hydromorphone Drugs 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 1
- HNJJXZKZRAWDPF-UHFFFAOYSA-N methapyrilene Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CS1 HNJJXZKZRAWDPF-UHFFFAOYSA-N 0.000 description 1
- 229960001869 methapyrilene Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229960001664 mometasone Drugs 0.000 description 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- PLPRGLOFPNJOTN-UHFFFAOYSA-N narcotine Natural products COc1ccc2C(OC(=O)c2c1OC)C3Cc4c(CN3C)cc5OCOc5c4OC PLPRGLOFPNJOTN-UHFFFAOYSA-N 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229960002657 orciprenaline Drugs 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
- 229960000395 phenylpropanolamine Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 229960005414 pirbuterol Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 229960001457 rimiterol Drugs 0.000 description 1
- IYMMESGOJVNCKV-SKDRFNHKSA-N rimiterol Chemical compound C([C@@H]1[C@@H](O)C=2C=C(O)C(O)=CC=2)CCCN1 IYMMESGOJVNCKV-SKDRFNHKSA-N 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- 229960005018 salmeterol xinafoate Drugs 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- KFVSLSTULZVNPG-UHFFFAOYSA-N terbutaline sulfate Chemical compound [O-]S([O-])(=O)=O.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1 KFVSLSTULZVNPG-UHFFFAOYSA-N 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0091—Inhalators mechanically breath-triggered
- A61M15/0096—Hindering inhalation before activation of the dispenser
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
- A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
- A61M15/007—Mechanical counters
Definitions
- the section of reduced diameter is integral to the housing.
- the portion of reduced cross sectional area may be formed by shaping the external casing.
- the portion of reduced cross sectional area may be formed by shaping any one of or any combination of the container body, the ferrule and the external casing.
- the pharmaceutical may, for example, be one which is suitable for the treatment of asthma.
- examples include salbutamol, beclomethasone, salmeterol, fluticasone, formoterol, terbutaline, sodium chromoglycate, budesonide and flunisolide, and physiologically acceptable salts (for example salbutamol sulphate, salmeterol xinafoate, fluticasone propionate, beclomethasone dipropionate, and terbutaline sulphate), solvates and esters, including combinations of two or more thereof.
- Individual isomers such as, for example, R-salbutamol, may also be used.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
- Nozzles (AREA)
Abstract
An inhalation apparatus for dispensing substances for inhalation. The inhalation apparatus comprises a housing, the housing comprising an air inlet and an outlet, the housing defining a socket for receiving therein a dispensing container, the dispensing container having a portion of reduced cross sectional area. The inhalation apparatus further comprises a section of reduced diameter intermediate the air inlet and the outlet. In use, the dispensing container is movable within the socket between positions one, two and three. In the first position (the rest position) the section of reduced diameter interfaces with the dispensing container to prevent or substantially prevent flow of air between the air inlet and the outlet. In the second position (the flow position) the section of reduced diameter is at least partially aligned with the portion of reduced cross sectional area of the dispensing container to thereby form a gap sufficient to enable a flow of air between the air inlet and the outlet. The third position is associated with dispensation of a product from the dispensing container into the flow of air.
Description
Dispensing apparatus
This invention relates to an inhalation apparatus for dispensing substances for inhalation and, in particular, but not exclusively, an apparatus for dispensing medicinal products in aerosol form from a pressurised dispensing container.
Apparatus for dispensing a metered dose of a medicinal product for inhalation by a user are well known. Examples of medicinal products dispensed in this manner include those used in the treatment of asthma. In order to maximise the effective inhalation of the medicinal product it is desirable for the dispensation of the medicinal product to occur part way through a user's inhalation cycle. It is known to provide an inhalation apparatus which enables the user to begin inhaling air before the product is dispensed into the air stream. This has previously been achieved using a dispensing apparatus with airflow valves comprising moving parts, such as the apparatus disclosed in GB2323041. A disadvantage of using airflow valves is that such apparatus requires a number of component parts which must be assembled during manufacture. In addition, the necessity for a moving stemblock can be problematic because an orifice in the stemblock needs to line up with the centre of the mouthpiece prior to actuation of the valve.
The present invention provides an inhalation apparatus comprising a housing, the housing comprising an air inlet and an outlet, the housing defining a socket for receiving therein a dispensing container, the dispensing container having a portion of reduced cross sectional area, the inhalation apparatus comprising a section of reduced diameter intermediate the air inlet and the outlet;
wherein, in use, the dispensing container is movable within the socket from a first, rest, position in which the section of reduced diameter interfaces with the dispensing container to prevent or substantially prevent flow of air between the air inlet and the outlet to a second, flow, position in which the section of reduced diameter is at least partially aligned with the portion of reduced cross sectional area of the dispensing container to thereby form a gap sufficient to enable a flow of air between the air inlet and the air outlet; the dispensing container being further movable in use into a third position associated with dispensation of a product from the dispensing container into the flow of air.
An advantage of the present invention is that an inexpensive apparatus is provided that allows the dispensation of the medicament to occur part way through the user's inhalation cycle. The apparatus can be formed from two components, fixed with respect to each other. The apparatus is therefore less complicated to manufacture than those described in the prior art.
Preferably, the section of reduced diameter is integral to the housing.
Preferably, the section of reduced diameter is an inward projection substantially perpendicular to the axis in which, in use, the dispensing container is movable.
In a first embodiment, the section of reduced diameter is formed by a component coupled to the housing.
Preferably, the component is an insert receivable in the socket of the housing. The insert may be annular and the insert may be coupled to the housing by means of an interference fit.
Preferably, the housing further comprises a non-return feature which allows insertion of the insert but prevents or impedes removal of the insert.
Preferably, the non-return feature is an angled projection presenting a sloped face on an air inlet side of the angled projection for allowing the insert to ride over the angled projection on insertion of the insert and presenting an abutment surface on an outlet side of the angled projection for preventing or impeding removal of the insert.
Alternatively, the non-return feature is a flexible barb projecting beyond the external diameter of the insert.
The inserted component may be formed from, for example, plastic or metal. The component may be coupled to the housing by means of bonding.
Preferably, the housing further comprises supports which support the section of reduced diameter.
Preferably the housing further comprises aligning ribs which ensure that the component is correctly aligned.
The air inlet may be provided by an open end of the housing and the outlet may be a mouthpiece.
In a second embodiment, the housing may comprise an upper housing part and a lower housing part which are connectable together.
The section of reduced diameter is located at the distal end of the upper housing part.
Preferably the upper housing part and the lower housing part are connectable together by a snap fit mechanism. The inhalation apparatus may be used with a dispensing container to form an inhalation apparatus assembly, wherein
- A -
the dispensing container has a portion of reduced cross sectional area.
Preferably, a cross section of the dispensing container at the portion of reduced cross sectional area of the dispensing container is substantially circular shaped.
Alternatively, the cross section of the dispensing container at the portion of reduced cross sectional area of the dispensing container is substantially non-circular in shape . The dispenser body may comprise a container body, a valve and a ferrule.
The portion of reduced cross sectional area may be formed by shaping the container body or by shaping the ferrule or a combination of shaping the container body and the ferrule.
Additionally or alternatively, the dispensing container may comprise an external casing in which a container body and or valve and or ferrule of the dispensing container is at least partially received. For example, the casing may be a sleeve or cap received over, or attached to, the container body.
The portion of reduced cross sectional area may be formed by shaping the external casing.
The portion of reduced cross sectional area may be formed by shaping any one of or any combination of the container body, the ferrule and the external casing.
The portion of reduced cross sectional area may be formed by shaping the container body or by shaping the ferrule or a combination of shaping the container body and the ferrule.
Alternatively, the dispensing container may comprises an external casing in which a container body and or valve
and or ferrule of the dispensing container is at least partially received.
The portion of reduced cross sectional area may be formed by shaping the external casing. The portion of reduced cross sectional area may be formed by shaping any one of or any combination of the container body, the ferrule and the external casing.
Alternatively or additionally, the inhalation apparatus assembly further comprises an ancillary unit which is coupled to the dispensing container.
The ancillary unit may be a dose counter unit.
The portion of reduced cross sectional area may be formed by shaping any one of or a combination of the dispensing container and the ancillary unit. Preferably, the ancillary unit is coupled to the dispensing container by one or more of a snapfit arrangement, weld or adhesive.
The inhalation apparatus may further comprises a dose counter mechanism to increment the number of doses taken or decrement the number of doses remaining on actuation of the apparatus .
It will be appreciated that the portion of reduced cross-sectional area must be formed by a feature of the dispensing container so that the portion of reduced cross- sectional area moves axially with the dispensing container. However, the portion of reduced cross-sectional area may be formed by any part of the dispensing container or any part of any component coupled to the dispensing container.
The dispensing apparatus may further comprise a dose counter mechanism to increment the number of doses taken or decrement the number of doses remaining on actuation of the apparatus .
The dispensing apparatus may be a pharmaceutical dispensing device, such as, for example, a pulmonary, nasal, or sub-lingual delivery device. A preferred use of the dispensing apparatus is as a pharmaceutical metered dose aerosol inhaler device. The term pharmaceutical, as used herein, is intended to encompass any pharmaceutical, compound, composition, medicament, agent or product which can be delivered or administered to a human being or animal, for example pharmaceuticals, drugs, biological and medicinal products. Examples include antiallergics, analgesics, bronchodilators, antihistamines, therapeutic proteins and peptides, antitussives, anginal preparations, antibiotics, anti-inflammatory preparations, hormones, or sulfonamides, such as, for example, a vasoconstrictive amine, an enzyme, an alkaloid, or a steroid, including combinations of two or more thereof. In particular, examples include isoproterenol [alpha- (isopropylaminomethyl) protocatechuyl alcohol], phenylephrine, phenylpropanolamine, glucagon, adrenochrome, trypsin, epinephrine, ephedrine, narcotine, codeine, atropine, heparin, morphine, dihydromorphinone, ergotamine, scopolamine, methapyrilene, cyanocobalamin, terbutaline, rimiterol, salbutamol, flunisolide, colchicine, pirbuterol, beclomethasone, orciprenaline, fentanyl, and diamorphine, streptomycin, penicillin, procaine penicillin, tetracycline, chlorotetracycline and hydroxytetracycline, adrenocorticotropic hormone and adrenocortical hormones, such as cortisone, hydrocortisone, hydrocortisone acetate and prednisolone, insulin, cromolyn sodium, and mometasone, including combinations of two or more thereof. The pharmaceutical may be used as either the free base or as one or more salts conventional in the art, such as, for example, acetate, benzenesulphonate, benzoate,
bicarbonate, bitartrate, bromide, calcium edetate, camsylate, carbonate, chloride, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, fluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isethionate, lactate, lactobionate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulphate, mucate, napsylate, nitrate, pamoate, (embonate) , pantothenate, phosphate, diphosphate, polygalacturonate, salicylate, stearate, subacetate, succinate, sulphate, tannate, tartrate, and triethiodide, including combinations of two or more thereof. Cationic salts may also be used, for example the alkali metals, e.g. Na and K, and ammonium salts and salts of amines known in the art to be pharmaceutically acceptable, for example glycine, ethylene diamine, choline, diethanolamine, triethanolamine, octadecylamine, diethylamine, triethylamine, l-amino-2-propanol-amino-2- (hydroxymethyl) propane-1, 3-diol, and l-(3,4- dihydroxyphenyl) -2 isopropylaminoethanol .
The pharmaceutical will typically be one which is suitable for inhalation and may be provided in any suitable form for this purpose, for example as a solution or powder suspension in a solvent or carrier liquid, for example ethanol, or isopropyl alcohol. Typical propellants are HFAl34a, HFA227 and di-methyl ether.
The pharmaceutical may, for example, be one which is suitable for the treatment of asthma. Examples include salbutamol, beclomethasone, salmeterol, fluticasone, formoterol, terbutaline, sodium chromoglycate, budesonide and flunisolide, and physiologically acceptable salts (for example salbutamol sulphate, salmeterol xinafoate,
fluticasone propionate, beclomethasone dipropionate, and terbutaline sulphate), solvates and esters, including combinations of two or more thereof. Individual isomers such as, for example, R-salbutamol, may also be used. As will be appreciated, the pharmaceutical may comprise of one or more active ingredients, an example of which is flutiform, and may optionally be provided together with a suitable carrier, for example a liquid carrier. One or more surfactants may be included if desired. Rigid components of the dispensing apparatus may be formed from, for example, polyester, nylon, acetal or similar.
Embodiments of the present invention will now be described, by way of example only, with reference to the accompanying drawings, in which:
Figure 1 is a schematic cross sectional view of a first embodiment of dispensing apparatus according to the present invention; Figure 2 is a schematic cross sectional view of a dispensing apparatus assembly comprising the dispensing apparatus of Figure 1 and a dispensing container received into a socket of the dispensing apparatus and with the dispensing container shown in a first, rest, position; Figure 3 is a schematic cross sectional view of the dispensing apparatus assembly of Figure 2 with the dispensing container shown in a second, flow, position;
Figure 4 is a schematic cross sectional view of the dispensing apparatus assembly of Figure 2 with the dispensing container shown in a third position associated with dispensation of a product from the dispensing container;
Figure 5A is a perspective view of an insert of the first embodiment of the present invention;
Figure 5B is a schematic cross sectional view of part of the housing of the dispensing apparatus of the first embodiment and includes the non return feature;
Figure 6 is a schematic cross sectional view of a second embodiment of dispensing apparatus according to the present invention;
Figure 7 is a schematic cross sectional view of a dispensing apparatus comprising the dispensing apparatus of Figure 6 and a dispensing container received into a socket of the dispensing apparatus and with the dispensing container shown in a first, rest, position;
Figure 8 is a schematic cross sectional view of the dispensing apparatus assembly of Figure 7 with the dispensing container shown in a second, flow, position; and
Figure 9 is a schematic cross sectional view of the dispensing apparatus assembly of Figure 7 with the dispensing container shown in a third position associated with dispensation of a product from the dispensing container .
A first embodiment of an inhalation apparatus assembly 50 is shown in Figures 2, 3 and 4. The inhalation apparatus assembly comprises an inhalation apparatus 1 and a dispensing container 6. Figure 1 shows the inhalation apparatus 1 without the dispensing container 6 inserted.
The dispensing container 6 consists of a body 7 and a metering valve 25 which itself is provided with a valve stem 8. The body 7 is formed as an open-topped cylindrical container which defines a storage volume for a product. A portion of reduced cross sectional area 9 is located towards
the open top of the body 7. The body 7 is closed by means of the metering valve 25 which is tightly connected to the body 7 by a ferrule 24 which is crimped to the upper end of the body 7 such that the portion of reduced cross sectional area 9 is located adjacent to the ferrule 24. The ferrule 24 comprises an aperture through which the valve stem 8 protrudes .
The inhalation apparatus 1 comprises a housing 2 and an annular insert 12. The housing 2 defines a socket 5 which is shaped to receive the dispensing container 6. The housing 2 includes an air inlet 3 at an upper end of the socket 5 and an outlet 4 off of a lower end of the socket. A valve stem receiving block 17 is located at the end of the socket 5 closest to the outlet 4. The valve stem receiving block comprises a conduit 27 shaped to receive the valve stem 8 and direct outflow from the valve stem 8 through an orifice towards the mouthpiece 22. Aligning ribs 18 are located within the socket 5 to ensure the correct alignment of the insert 12 within the housing 2 and the container of the inhalation apparatus assembly. An angled projection 19 is present within the socket 5 adjacent to the location 26 where, on assembly, the insert is located. The angled projection 19 is shown in Figure 5B and is located on the air inlet 3 side of the location 26. Supports 23 are present within the socket 5 adjacent to the location 26 where, on assembly, the insert is located. The supports 23 are located on the outlet 4 side of the location 26. The outlet 4 is a mouthpiece 22. The angled projection 19 consists of a sloped face 20 and an abutment surface 21. The purpose of the angled projection 19 is to ensure that the insert 12 can be inserted on assembly but, once inserted, cannot easily be moved or removed.
The insert 12 is an annular member wherein the external diameter is shaped to fit into a location 26 with a correspondingly shaped internal diameter on the inside of the housing 2 within the socket 5. The correspondence between the location 26 and the insert 12 ensures that the insert 12 remains positioned in the location 26 by means of an interference fit 13. On assembly, the internal diameter of the insert 12 provides a section of reduced diameter 10 when compared with a remainder of the socket 5. During assembly of the inhalation apparatus 1 the annular insert 12 is inserted into the location 26 with a correspondingly shaped internal diameter within the housing 2 via the air inlet end of the housing 2. The sloped face 20 of the angled projection 19 allows the insert 12 to ride over the angled projection 19 and the abutment surface 21 prevents or impedes the subsequent removal of the insert 12. The supports 23 act to further prevent or impede the movement of the insert 12 in the direction of the outlet 4. In addition, the supports 23 ensure the insert 12 is correctly aligned with respect to the housing 2.
In use, the dispensing container 6 is received in the socket 5 of the housing 2 with the valve stem 8 located as a push-fit in the conduit 27 of the valve stem receiving block 17 as shown in Figure 2. The process of operation requires the user to inhale on the mouthpiece 22 and then to depress the dispensing container 6 with respect to the inhalation apparatus 1 in one continuous movement. When depressed the dispensing container 6 moves from a first, rest, position through a second, flow, position to a third position associated with dispensation.
In the first, rest, position, as shown in Figure 2, the section of reduced diameter 10 of the inhalation apparatus 1
interfaces with the dispensing container 6 such that there is no gap or only a small gap between the insert 12 and the dispensing container 6. Consequently this first, rest, position acts to prevent or substantially prevent the flow of air between the air inlet 3 and the outlet 4. In use, a user will inhale on the mouthpiece 22. In this position, since a flow of air between the air inlet 3 and the outlet 4 is prevented or substantially prevented, the resistance to inhalation is large. As a result the user will inhale slowly.
Next, the user depresses the dispensing container 6 at the opposite end to the metering valve 25 to move the dispensing container 6 with respect to the apparatus 1 into the second, flow, position which is illustrated in Figure 3. In this position the portion of reduced cross sectional area 9 of the dispensing container 6 is at least partially- aligned with the section of reduced diameter 10 of the apparatus 1 thereby forming a gap 11 between the housing 2 and the dispensing container 6 sufficient to enable a substantial flow of air between the air inlet 3 and the outlet 4. Consequently, the user will inhale more rapidly than when the apparatus was in the first, rest, position.
The user continues to move the dispensing container 6 with respect to the apparatus 1 into a third position shown in Figure 4. In this position the gap 11 is maintained between the housing 2 and the dispensing container 6. Also, the dispensing the valve stem 8 has moved relative to the remainder of the metering valve sufficient to actuate the valve 25 resulting in dispensation of the product into the already established air flow via the valve stem 8 and the conduit 27 of the valve stem receiving block 17. The user
continues to inhale the air flow which now contains the dispensed product.
Rigid components of the apparatus may be made using one or more of the following materials: polypropylene (PP), Acetal (POM), Polyester (PBT), Acrylonitrile Butadiene
Styrene (ABS) , Co-polyester, Stainless steel, and aluminium.
In one example tested, when in the first, rest, position and tested at a flow rate of 28.3 litres per minute, the pressure drop between the air inlet and the outlet is likely to be in excess of 2500 Pascals. When in the third position and tested at a flow rate of 28.3 litres per minute, the pressure drop between the air inlet and the outlet is likely to be less than 120 Pascals.
The embodiment described above may be varied by using an insert which is not annular. The essential requirement is that in the first, rest, position the size and shape of the opening in the insert 12 closely matches the external size and shape of the part of the container 6 against which it interfaces so that no or a minimal airflow is produced on inhalation. For example, the container 6 could be square shaped in which case the opening in the insert would also be square shaped. It should be further noted that in the second, flow, position it is not necessary for a gap to be formed all the way round the container 6. For example the container may simply comprise an indentation at one or more points around its circumference which constitute one or more discontinuities in the cross-section of the container body. In this way alignment of an indentation with an insert produces the required gap to allow an airflow to be established.
A second embodiment of the present invention is illustrated in Figure 6 to Figure 9. The same reference
numbers have been used to identify parts which correspond to those of the first embodiment.
In this second embodiment the housing 2 includes an upper housing part 14 and a lower housing part 15. The section of reduced diameter 10 of the apparatus 1 is integral to the upper housing part and is formed by an inwardly directed flange formed at a lower end of the upper housing part 14. The upper housing part 14 is coupled to the lower housing part 15 using a snap fit mechanism 16. Figure 6 shows the inhalation apparatus 1 of the second preferred embodiment.
Figure 7 shows the inhalation apparatus assembly 50 including the inhalation apparatus 1 and a dispensing container 6 in the first, rest, position. The dispensing container 6 is of the same type as described above in relation to the first embodiment. Figure 8 shows the apparatus 1 and a dispensing container 6 with a portion of reduced cross sectional area 9 in the second, flow, position. Figure 9 shows the apparatus 1 and dispensing container 6 with a portion of reduced cross sectional area 9 in the third position associated with dispensation of the product .
Assembly of the second embodiment of the invention requires the upper housing 14 and the lower housing 15 to be connected together. The second embodiment of the present invention is operated in the same way as the first embodiment of the present invention.
Claims
1. An inhalation apparatus comprising a housing, the housing comprising an air inlet and an outlet, the housing defining a socket for receiving therein a dispensing container, the dispensing container having a portion of reduced cross sectional area, the inhalation apparatus comprising a section of reduced diameter intermediate the air inlet and the outlet; wherein, in use, the dispensing container is movable within the socket from a first, rest, position in which the section of reduced diameter interfaces with the dispensing container to prevent or substantially prevent flow of air between the air inlet and the outlet to a second, flow, position in which the section of reduced diameter is at least partially aligned with the portion of reduced cross sectional area of the dispensing container to thereby form a gap sufficient to enable a flow of air between the air inlet and the outlet; the dispensing container being further movable in use into a third position associated with dispensation of a product from the dispensing container into the flow of air.
2. The inhalation apparatus as claimed in claim 1 wherein the section of reduced diameter is integral to the housing.
3. The inhalation apparatus as claimed in claim 2 wherein the section of reduced diameter is an inward projection substantially perpendicular to an axis in which, in use, the dispensing container is movable.
4. The inhalation apparatus as claimed in claim 2 or claim 3 wherein the housing and the section of reduced diameter are moulded as an integral component.
5. The inhalation apparatus as claimed in claim 2 or claim 3 wherein the housing comprises an upper housing part and a lower housing part which are connectable together.
6. The inhalation apparatus as claimed in claim 5 wherein the section of reduced diameter is located at the distal end of the upper housing part.
7. The inhalation apparatus as claimed in claim 5 or claim 6 wherein the upper housing part and the lower housing part are connectable together by a snap fit mechanism.
8. The inhalation apparatus as claimed in claim 1 wherein the section of reduced diameter is formed by a component coupled to the housing.
9. The inhalation apparatus as claimed in claim 8 wherein the component is an insert receivable in the socket of the housing.
10. The inhalation apparatus as claimed in claim 9 wherein the insert is annular.
11. The inhalation apparatus as claimed in claim 9 or claim 10 wherein the insert is coupled to the housing by means of an interference fit.
12. The inhalation apparatus of any of claims 9 to 11 wherein the housing further comprises a non-return feature which allows insertion of the insert but prevents or impedes removal of the insert.
13. The inhalation apparatus as claimed in claim 12 wherein the non-return feature is an angled projection presenting a sloped face on an air inlet side of the angled projection for allowing the insert to ride over the angled projection on insertion of the insert and presenting an abutment surface on an outlet side of the angled projection for preventing or impeding removal of the insert.
14. The inhalation apparatus as claimed in any of claims 8 to 13 wherein the component is coupled to the housing by means of bonding.
15. The inhalation apparatus as claimed in any of claims 8 to 14 wherein the housing further comprises supports which support the section of reduced diameter.
16. The inhalation apparatus as claimed in any of claims 8 to 15 wherein the housing further comprises aligning ribs which ensure that the component is correctly aligned.
17. The inhalation apparatus as claimed in any preceding claim wherein the air inlet is provided by an open end of the housing.
18. The inhalation apparatus as claimed in any preceding claim wherein the outlet is a mouthpiece.
19. An inhalation apparatus assembly comprising the inhalation apparatus of any preceding claim and a dispensing container wherein the dispensing container has a portion of reduced cross sectional area.
20. The inhalation apparatus assembly as claimed in claim 19 wherein a cross section of the dispensing container at the portion of reduced cross sectional area of the dispensing container is substantially circular shaped.
21. The inhalation apparatus assembly as claimed in claim 19 wherein a cross section of the dispensing container at the portion of reduced cross sectional area of the dispensing container is substantially non-circular in shape.
22. The inhalation apparatus assembly as claimed in any of claims 19 to 21 wherein the dispensing container comprises a container body, a valve and a ferrule.
23. The inhalation apparatus assembly as claimed in claim 22 wherein the portion of reduced cross sectional area is formed by shaping the container body or by shaping the ferrule or a combination of shaping the container body and the ferrule.
24. The inhalation apparatus assembly as claimed in any one of claims 19 to 21 wherein the dispensing container comprises an external casing in which a container body and or valve and or ferrule of the dispensing container is at least partially received.
25. The inhalation apparatus assembly as claimed in claim 24 wherein the portion of reduced cross sectional area is formed by shaping the external casing.
26. The inhalation apparatus assembly as claimed in claim 24 wherein the portion of reduced cross sectional area is formed by shaping any one of or any combination of the container body, the ferrule and the external casing.
27. The inhalation apparatus assembly as claimed in any one of claims 19 to 22 wherein the inhalation apparatus assembly further comprises an ancillary unit which is coupled to the dispensing container.
28. The inhalation apparatus assembly as claimed in claim 27 wherein the ancillary unit is a dose counter unit.
29. The inhalation apparatus assembly as claimed in claim 27 or 28 wherein the portion of reduced cross sectional area is formed by shaping any one of or a combination of the dispensing container and the ancillary unit.
30. The inhalation apparatus as claimed in any one of claims 27 to 29 wherein the ancillary unit is coupled to the dispensing container by one or more of a snapfit arrangement, weld or adhesive.
31. The inhalation apparatus of any preceding claim wherein the inhalation apparatus further comprises a dose counter mechanism to increment the number of doses taken or decrement the number of doses remaining on actuation of the apparatus .
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0711794A GB2450327A (en) | 2007-06-18 | 2007-06-18 | Inhaler with air flow control |
| GB0711794.8 | 2007-06-18 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2008155537A2 true WO2008155537A2 (en) | 2008-12-24 |
| WO2008155537A3 WO2008155537A3 (en) | 2009-03-12 |
Family
ID=38332324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/GB2008/002071 WO2008155537A2 (en) | 2007-06-18 | 2008-06-17 | Dispensing apparatus |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB2450327A (en) |
| WO (1) | WO2008155537A2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2604323T3 (en) | 2010-11-30 | 2017-03-06 | Teva Pharmaceutical Industries Ltd. | Inhalers with housing caps for inhalers |
| GB2594048B (en) * | 2020-04-04 | 2022-12-14 | Purcell Global Ltd | Inhaler systems |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3302834A (en) * | 1964-08-11 | 1967-02-07 | Fisous Pharmaceuticals Ltd | Aerosol applicators |
| US5460171A (en) * | 1991-11-15 | 1995-10-24 | Pesenti; Yvan | Synchronization device for aerosol appliances with pressurized regulating bottle |
| GB2323041A (en) * | 1997-03-14 | 1998-09-16 | Bespak Plc | Inhalation apparatus |
| US5904139A (en) * | 1997-03-28 | 1999-05-18 | Hauser; Stephen G. | Breath coordinated inhaler |
| US6415785B1 (en) * | 1999-05-24 | 2002-07-09 | Jack W. Stage | Self closing diaphragm type valve with primary peripheral and secondary central openings |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6615826B1 (en) * | 1999-02-26 | 2003-09-09 | 3M Innovative Properties Company | Slow spray metered dose inhaler |
-
2007
- 2007-06-18 GB GB0711794A patent/GB2450327A/en not_active Withdrawn
-
2008
- 2008-06-17 WO PCT/GB2008/002071 patent/WO2008155537A2/en active Application Filing
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3302834A (en) * | 1964-08-11 | 1967-02-07 | Fisous Pharmaceuticals Ltd | Aerosol applicators |
| US5460171A (en) * | 1991-11-15 | 1995-10-24 | Pesenti; Yvan | Synchronization device for aerosol appliances with pressurized regulating bottle |
| GB2323041A (en) * | 1997-03-14 | 1998-09-16 | Bespak Plc | Inhalation apparatus |
| US5904139A (en) * | 1997-03-28 | 1999-05-18 | Hauser; Stephen G. | Breath coordinated inhaler |
| US6415785B1 (en) * | 1999-05-24 | 2002-07-09 | Jack W. Stage | Self closing diaphragm type valve with primary peripheral and secondary central openings |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008155537A3 (en) | 2009-03-12 |
| GB0711794D0 (en) | 2007-07-25 |
| GB2450327A (en) | 2008-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1758631B1 (en) | Dispensing apparatus with counter | |
| EP1787668B1 (en) | Aerosol dispensing apparatus | |
| EP1778566B1 (en) | Improvements in metering valves for dispensers | |
| US7793806B2 (en) | Metering valve | |
| US20080283541A1 (en) | Dispensing apparatus | |
| EP2028132A1 (en) | Improvements in or relating to dispensing apparatus | |
| US9517314B2 (en) | Dose indicator device | |
| US9132247B2 (en) | Dose indicator device | |
| WO2015114337A1 (en) | Dose counter and dispensing apparatus | |
| WO2008087369A1 (en) | Improvements in or relating to dispensing apparatus | |
| WO2008155537A2 (en) | Dispensing apparatus | |
| WO2010133817A1 (en) | Valve assemblies, dispensing containers and kits therefore | |
| US8616197B2 (en) | Dispensing apparatus | |
| GB2538285A (en) | A fluid delivery device | |
| GB2464943A (en) | A valve stem for a metering valve | |
| GB2401925A (en) | Valve for pressurised dispensing container |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08762395 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 08762395 Country of ref document: EP Kind code of ref document: A2 |